CAS: 70458-96-7; 1-Ethyl-6-Fluoro-4-Oxo-7-(Piperazin-1-yl)-1,4-Dihydroquinoline-3-Carboxylic Acid

上下游产品

CAS号74011-47-5 ethyl 1-ethyl-6... | CAS号110-85-0 哌嗪 | CAS号68077-26-9 7-氯-1-乙基-6-氟-4-... | CAS号7440-44-0 活性炭 | CAS号118476-20-3 1-Ethyl-6-fluor... | CAS号7803-57-8 水合肼 | CAS号103258-03-3 1-ethyl-6-fluor... | CAS号142-63-2 哌嗪(六水) | CAS号110719-50-1 1-ethyl-6-fluor... | CAS号109142-49-6 N-羟基诺氟沙星 | CAS号70458-92-3 培氟沙星 | CAS号100587-52-8 琥诺沙星 | CAS号103175-73-1 1-ethyl-6-fluor... | CAS号70458-97-8 1-ethyl-6-fluor... | CAS号74011-56-6 7-(4-乙酰基哌嗪-1-基)... | CAS号75001-63-7 7-amino-1-ethyl... | CAS号75001-77-3 norfloxacin ep ... | CAS号85195-76-2 1-ethyl-6-fluor...

7-(4-(Tert-Butoxycarbonyl)Piperazin-1-yl)-1-Ethyl-6-Fluoro-4-Oxo-1,4-Dihydroquinoline-3-Carboxylic Acid置于三氟乙酸体系中,用 二氯甲烷 作为反应溶剂,化学反应 4.0H,以68.9%的收率获得产物诺氟沙星
参考文献: Antibiotic Resistance Breakers[fr] Agents De Rupture De Résistance Aux Antibiotiques
标题: Antibiotic Resistance Breakers[fr] Agents De Rupture De Résistance Aux Antibiotiques
摘要:该发明涉及公式(a1)的抗生素化合物及其药学上可接受的盐,溶剂化合物,互变异构体和它们的组合,其中x和l是可选的连接物,Ra或r1中的一个包括ar1,其中ar1是一种抗生素耐药性破坏基团,包括可选择取代的c6-10芳基,C7-13芳基烷基,C5-10杂芳基,C6-13杂芳基烷基,C5-10杂环烷基,C6-13杂环烷基,C3-10碳环烷基,C4-13碳环烷基,-C(=nr')-Nr'R''或-ch2-Ch=ch2基团;在将该化合物用于细菌感染后,该基团减少或预防外流.该发明还公开了包括公式(a1)化合物的药物组合物以及将这些化合物用作药物的用途,特别是用于治疗细菌感染,如耐药性细菌感染.

专利信息

专利号:US-9353057-B2
优先权日:2003-12-30
标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
发明人：GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
权利人:XENOPORT INC
摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

专利号:US-11274081-B2
优先权日:2016-05-30
标 题:Process for the synthesis of ivacaftor
发明人：REDDY DUMBALA SRINIVASA; KULKARNI AMOL ARVIND; NATARAJAN VASUDEVAN; SHARMA MRITYUNJAY KESHAVPRASAD
权利人:COUNCIL SCIENT IND RES
摘要:The present disclosed an improved process for the synthesis of ivacaftor starting from indole acetic acid ester which can be performed in batch as well as continuous flow synthesis. The present invention further disclosed to a continuous process for the synthesis of compound of formula (II) or formula (III) from compound of formula (I) in continuous flow reactor.

专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人：YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-2024197774-A1
优先权日:2021-04-16
标 题:Synthesis of Antimicrobial PVP-coated Bismuth Nanoparticles
发明人：LOPEZ-RIBOT JOSE; VAZQUEZ-MUNOZ ROBERTO
权利人:UNIV TEXAS
摘要:Described herein is a facile, fast, and economical method for the synthesis of BAL-mediated PVP-BiNPs, using basic laboratory instruments and reagents readily available in most laboratories.

专利号:US-7211590-B2
优先权日:2002-08-01
标 题:Nitrosated proton pump inhibitors, compositions and methods of use
发明人：FANG XINQIN; GARVEY DAVID S; LETTS L GORDON
权利人:NITROMED INC
摘要:The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti-Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.

专利号:US-11332444-B2
优先权日:2018-04-25
标题:Method for the hydrolysis of quinolonecarboxylic esters
发明人：FEY PETER; BERWE MATHIAS; WIRTHS Joerg; WISCHNAT RALF; LONGERICH MARKUS; DIETZEL ANTJE
权利人:BAYER ANIMAL HEALTH GMBH
摘要:Quinolonecarboxylic esters of the general formula (II) are hydrolyzed to quinolonecarboxylic acids of the general formula (I):The method comprises the step A):A) reacting compounds of the formula (II) with a mixture comprising acetic acid, sulfuric acid and waterIn step A), ≥30 to ≤40 mol of acetic acid, ≥0.3 to ≤1 mol of sulfuric acid and ≥0.9 to ≤2.5 mol of water are used per mole of compounds of the formula (II). The method is particularly suitable for the synthesis of the intermediate (I) in the synthesis of pradofloxacin.